New hope for aggressive lung cancer: can adding a second immune drug help patients live longer?
NCT ID NCT04665856
Summary
This study is testing whether adding a new drug called tiragolumab to a standard treatment regimen can better control advanced small cell lung cancer. It involved 123 patients in China who had not yet received any treatment for their extensive-stage disease. The goal is to see if the new combination can slow cancer growth and help patients live longer compared to the standard treatment alone.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital
Beijing, 100142, China
-
Beijing Chest Hospital
Beijing, 101149, China
-
Cancer Center of Guangzhou Medical University
Guangzhou, 510000, China
-
Cancer Hospital of Shantou University Medical College
Shantou, 515041, China
-
Fudan University Shanghai Cancer Center
Shanghai, 200120, China
-
Fujian Provincial Cancer Hospital
Fuzhou, 350014, China
-
Harbin Medical University Cancer Hospital
Harbin, 150081, China
-
Henan Cancer Hospital
Zhengzhou, 450008, China
-
Shanghai Chest Hospital
Shanghai, 200000, China
-
Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
Hangzhou, 310016, China
-
The 1st Affiliated Hospital of Nanchang Unversity
Nanchang, 330006, China
-
Wuhan Union Hospital Tongji Medical College, Huazhong University of Science and Technology
Wuhan, 430022, China
-
Zhejiang Cancer Hospital
Hangzhou, 310022, China
-
Zhongshan Hospital Fudan University
Shanghai, 200032, China
-
the First Affiliated Hospital of Bengbu Medical College
Bengbu, 233000, China
-
the First Hospital of Jilin University
Changchun, 130021, China
Conditions
Explore the condition pages connected to this study.